<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01443442</url>
  </required_header>
  <id_info>
    <org_study_id>MAC-06-11</org_study_id>
    <nct_id>NCT01443442</nct_id>
  </id_info>
  <brief_title>Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis</brief_title>
  <official_title>A Single-Center, Masked, Randomized Study Comparing Bepreve (Bepotastine Besilate) 1.5% - H1 Specific Antihistamine vs. Alrex (Loteprednol Etabonate) 0.2% - Corticosteroid in Subjects With Moderate to Severe Allergic Conjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern California College of Optometry at Marshall B. Ketchum University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southern California College of Optometry at Marshall B. Ketchum University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allergic conjunctivitis (AC) afflicts approximately 20% of the US population. Typically,&#xD;
      patients manifest symptoms in the spring, summer and fall, when airborne allergens are at&#xD;
      their peak. Patients may also be afflicted year-round, if sensitive to allergens such as dust&#xD;
      mites or pet dander. Signs and symptoms of allergic conjunctivitis are conjunctival&#xD;
      hyperemia, ocular itching, conjunctival and eyelid edema, papillary hypertrophy, tearing and&#xD;
      burning.&#xD;
&#xD;
      This is a randomized clinical study to evaluate the efficacy of Bepreve® (bepotastine&#xD;
      besilate 1.5% ophthalmic solution) compared to Alrex® (loteprednol etabonate 0.2%) in the&#xD;
      treatment of moderate to severe allergic conjunctivitis in patient over the age of 18 years.&#xD;
      The study will be a two-week study with four visits. Ocular signs (eye redness( and symptoms&#xD;
      (itching) will be monitored as outcome variables.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigator and Study Center:&#xD;
&#xD;
      Judy Tong, OD Eye Care Center Southern California College of Optometry&#xD;
&#xD;
      Test Product, Dose and Mode of Administration:&#xD;
&#xD;
      Bepreve (bepotastine besilate ophthalmic solution) 1.5% bid ou vs. Alrex (loteprednol&#xD;
      etabonate ophthalmic suspension) 0.2% qid ou&#xD;
&#xD;
      Study Title:&#xD;
&#xD;
      A Single-Center, Masked, Randomized Study Comparing Bepreve (bepotastine besilate) 1.5% - H1&#xD;
      Specific Antihistamine vs. Alrex (loteprednol etabonate) 0.2% - Corticosteroid in Subjects&#xD;
      with Moderate to Severe Allergic Conjunctivitis&#xD;
&#xD;
      Primary Objective(s):&#xD;
&#xD;
      The primary objective of this study is to compare the efficacy of Bepreve (bepotastine&#xD;
      besilate) 1.5% ophthalmic solution compared to Alrex (loteprednol etabonate) 0.2% in the&#xD;
      treatment of moderate to severe allergic conjunctivitis in patients over the age of 18 years&#xD;
      of age&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
      Interventional, Randomized, Parallel Arm, Investigator Masked&#xD;
&#xD;
      Study Population:&#xD;
&#xD;
      Subjects over the age of 18 years of age with moderate to severe allergic conjunctivitis.&#xD;
&#xD;
      Duration of Treatment: 14 days&#xD;
&#xD;
      Efficacy Assessments: Itching, Bulbar conjunctival injection, Bulbar conjunctival chemosis&#xD;
&#xD;
      Safety Assessments: N/A&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Ocular Itching at 14 Days</measure>
    <time_frame>Change from Baseline in Ocular Itching at 14 Days</time_frame>
    <description>Ocular Itching Scale. Scale is 0 - 4 in 0.5 scale unit increments. 0 equals no Itch. 4 equals most severe itch. No calculation details are necessary as the change is calculated as the latest time point minus the earliest time point.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>Bepreve</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.5% bepotastine besilate, drops, twice per day, for two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alrex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment with 0.2 % loteprednol etabonate, drops, four times per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bepotastine besilate, 1.5%</intervention_name>
    <description>Topical ocular aqueous formulation, oen drop per instillation, twice per day for 14 days</description>
    <arm_group_label>Bepreve</arm_group_label>
    <other_name>Bepreve</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loteprednol etabonate</intervention_name>
    <description>Topical ocular aqueous formulation, one drop per instillation, four times per day for 14 days</description>
    <arm_group_label>Alrex</arm_group_label>
    <other_name>Alrex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Moderate to severe allergic subjects (≥ 2.5 on a 0.0 to 4.0 itching scale AND&#xD;
&#xD;
             &gt; grade 2.0 bulbar redness using validated (Efron) scale)&#xD;
&#xD;
          -  Must be able to understand and sign an informed consent form that has been approved by&#xD;
             the Institutional Review Board (IRB).&#xD;
&#xD;
          -  Can comply with instillation of study drug&#xD;
&#xD;
          -  Must be able to comply with the visit schedule and other requirements of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who use daily wear (5-7 days / week, 6-16 hours/day)25 disposable soft&#xD;
             hydrogel or silicone hydrogel contact lenses will be included in the study if they&#xD;
             have been consistently wearing the same brand and have been using the same care&#xD;
             solution for one month or longer. They will be asked to not wear their soft contact&#xD;
             lenses to the eligibility visit (three days of no lens wear) and be willing to&#xD;
             discontinue lens wear during the two weeks of the study because of the incompatibility&#xD;
             of medicated eye drop instillation with contact lens wear and the potential&#xD;
             confounding effect of contact lenses and care solutions.&#xD;
&#xD;
          -  Active inflammation of the cornea, iris, anterior chamber&#xD;
&#xD;
          -  Active or suspected herpetic eye disease (simplex, vaccinia, varicella)&#xD;
&#xD;
          -  Active or suspected mycobacterial or acanthamoeba infection&#xD;
&#xD;
          -  Active for suspected fungal disorders of the eye&#xD;
&#xD;
          -  Persistent and significant dry eye syndrome&#xD;
&#xD;
          -  Known allergy, contraindications or hypersensitivity to loteprednol, bepotastine, or&#xD;
             its components&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Use of topical eye drops, topical or systemic antihistamines, topical, nasal or&#xD;
             systemic corticosteroids, immunosuppressive or immunomodulating agents, decongestants,&#xD;
             aspirin, or non-steroidal antiinflammatory (NSAIDs) during the two weeks prior to the&#xD;
             study.&#xD;
&#xD;
          -  Participation in any other study within 30 days of this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judy Tong, OD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southern California College of Optometry at Marshall B. Ketchum University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eye Car Center, Southern California college of Optometry</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92831</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Care Center, Southern Caalifornia College of Optometry</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92831</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>September 27, 2011</study_first_submitted>
  <study_first_submitted_qc>September 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2011</study_first_posted>
  <results_first_submitted>January 26, 2016</results_first_submitted>
  <results_first_submitted_qc>July 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 6, 2019</results_first_posted>
  <last_update_submitted>July 16, 2019</last_update_submitted>
  <last_update_submitted_qc>July 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Conjunctivitis</keyword>
  <keyword>Allergic</keyword>
  <keyword>Bepotastine besilate</keyword>
  <keyword>Loteprednol etabonate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loteprednol Etabonate</mesh_term>
    <mesh_term>Bepotastine besilate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bepreve</title>
          <description>1.5% bepotastine besilate, drops, twice per day, for two weeks&#xD;
bepotastine besilate, 1.5%: Topical ocular aqueous formulation, oen drop per instillation, twice per day for 14 days</description>
        </group>
        <group group_id="P2">
          <title>Alrex</title>
          <description>treatment with 0.2 % loteprednol etabonate, drops, four times per day&#xD;
Loteprednol etabonate: Topical ocular aqueous formulation, one drop per instillation, four times per day for 14 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bepreve</title>
          <description>1.5% bepotastine besilate, drops, twice per day, for two weeks&#xD;
bepotastine besilate, 1.5%: Topical ocular aqueous formulation, oen drop per instillation, twice per day for 14 days</description>
        </group>
        <group group_id="B2">
          <title>Alrex</title>
          <description>treatment with 0.2 % loteprednol etabonate, drops, four times per day&#xD;
Loteprednol etabonate: Topical ocular aqueous formulation, one drop per instillation, four times per day for 14 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.3" spread="16.3"/>
                    <measurement group_id="B2" value="53.0" spread="13.0"/>
                    <measurement group_id="B3" value="51.1" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Ocular Itching at 14 Days</title>
        <description>Ocular Itching Scale. Scale is 0 - 4 in 0.5 scale unit increments. 0 equals no Itch. 4 equals most severe itch. No calculation details are necessary as the change is calculated as the latest time point minus the earliest time point.</description>
        <time_frame>Change from Baseline in Ocular Itching at 14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bepreve</title>
            <description>1.5% bepotastine besilate, drops, twice per day, for two weeks&#xD;
bepotastine besilate, 1.5%: Topical ocular aqueous formulation, oen drop per instillation, twice per day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Alrex</title>
            <description>treatment with 0.2 % loteprednol etabonate, drops, four times per day&#xD;
Loteprednol etabonate: Topical ocular aqueous formulation, one drop per instillation, four times per day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Ocular Itching at 14 Days</title>
          <description>Ocular Itching Scale. Scale is 0 - 4 in 0.5 scale unit increments. 0 equals no Itch. 4 equals most severe itch. No calculation details are necessary as the change is calculated as the latest time point minus the earliest time point.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" spread="0.53"/>
                    <measurement group_id="O2" value="1.82" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bepreve</title>
          <description>1.5% bepotastine besilate, drops, twice per day, for two weeks&#xD;
bepotastine besilate, 1.5%: Topical ocular aqueous formulation, oen drop per instillation, twice per day for 14 days</description>
        </group>
        <group group_id="E2">
          <title>Alrex</title>
          <description>treatment with 0.2 % loteprednol etabonate, drops, four times per day&#xD;
Loteprednol etabonate: Topical ocular aqueous formulation, one drop per instillation, four times per day for 14 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jerry R. Paugh, OD, PhD</name_or_title>
      <organization>SCCO at MBKU</organization>
      <phone>714-449-7487</phone>
      <email>jpaugh@ketchum.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

